Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Boquimpani C, Pasquini R, Clark RE, Dubruille V, Flinn IW, Kyrcz-Krzemien S, Medras E, Zanichelli M, Bendit I, Cacciatore S, Titorenko K, Aimone P, Saglio G, Hochhaus A. Kantarjian HM, et al. Among authors: medras e. Leukemia. 2021 Feb;35(2):440-453. doi: 10.1038/s41375-020-01111-2. Epub 2021 Jan 7. Leukemia. 2021. PMID: 33414482 Free PMC article. Clinical Trial.
Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Boquimpani C, Pasquini R, Clark RE, Dubruille V, Flinn IW, Kyrcz-Krzemien S, Medras E, Zanichelli M, Bendit I, Cacciatore S, Titorenko K, Aimone P, Saglio G, Hochhaus A. Kantarjian HM, et al. Among authors: medras e. Leukemia. 2021 Jul;35(7):2142-2143. doi: 10.1038/s41375-021-01306-1. Leukemia. 2021. PMID: 34108614 Free PMC article. No abstract available.
Quality of Life and Adherence to Therapy in Patients With Chronic Myeloid Leukemia Treated With Nilotinib as a Second-Line Therapy: A Multicenter Prospective Observational Study.
Sacha T, Góra-Tybor J, Wąsak-Szulkowska E, Kyrcz-Krzemień S, Mędraś E, Becht R, Bober G, Kotowska A, Wącław J, Hellmann A. Sacha T, et al. Among authors: medras e. Clin Lymphoma Myeloma Leuk. 2017 May;17(5):283-295. doi: 10.1016/j.clml.2017.01.001. Epub 2017 Jan 10. Clin Lymphoma Myeloma Leuk. 2017. PMID: 28185798
Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 527 Patients From the Polish Adult Leukemia Group Registry.
Gora-Tybor J, Sacha T, Wącław J, Niesiobędzka-Krężel J, Grzybowska-Izydorczyk O, Mędraś E, Dereń-Wagemann I, Patkowska E, Seferyńska I, Lewandowski K, Wache A, Blajer-Olszewska B, Wątek M, Kotwica-Mojzych K, Wasilewska E, Warzocha K, Jamroziak K. Gora-Tybor J, et al. Among authors: medras e. Clin Lymphoma Myeloma Leuk. 2018 Jul;18(7):e283-e285. doi: 10.1016/j.clml.2018.05.001. Epub 2018 May 9. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29778693 No abstract available.
A multicenter prospective study on efficacy and safety of imatinib generics: A report from Polish Adult Leukemia Group imatinib generics registry.
Sacha T, Góra-Tybor J, Szarejko M, Bober G, Grzybowska-Izydorczyk O, Niesiobędzka-Krężel J, Dudziński M, Wasilewska E, Myśliwiec K, Gil J, Gniot M, Pietkun I, Mędraś E, Hołojda J, Wącław J, Giannopoulos K. Sacha T, et al. Among authors: medras e. Am J Hematol. 2017 Jul;92(7):E125-E128. doi: 10.1002/ajh.24748. Epub 2017 May 26. Am J Hematol. 2017. PMID: 28376561 Free article. Clinical Trial. No abstract available.
[Haematologic changes in gastritic cancer].
Gabryś K, Nowicka J, Medraś E, Pabisek D, Mazur G, Jeleń M. Gabryś K, et al. Among authors: medras e. Pol Tyg Lek. 1995;50(1-35):809-11. Pol Tyg Lek. 1995. PMID: 11785203 Review. Polish.
15 results